Keyword: Abbott Laboratories
The DOJ signed on to a whistleblower suit against one of Alere’s now-defunct subsidiaries over diabetic testing supplies and blood glucose readers.
Novo Nordisk started a new collaboration with Abbott and its Freestyle Libre line of digital health tools and continuous glucose monitoring devices.
Abbott has exercised a three-year-old option to purchase Cephea Valve Technologies, a developer of mitral heart valve replacements.
Abbott received FDA approval for its Amplatzer Piccolo Occluder, which it describes as the world’s first implant for babies as little as two pounds.
After catapulting up five ranks on the list between 2016 and 2017, Abbott Laboratories will be looking to hold on to its third-place spot through 2024, on the laurels of its $25 billion acquisition of St. Jude Medical in January of last year.
While most of the world’s top 10 medtech companies are expected to defend their relative rankings in the coming years, ambitious or inspired M&A deals could give companies lower on the list the oomph to move up and reap billions in additional sales in new market segments.
A clinical trial showed that Abbott’s MitraClip improved survival in patients with leaky heart valves damaged by heart failure.
The phase 2 trial linked the Nrf2 activator to improvements in estimated glomerular filtration rate, a measure of kidney damage.
The FDA approved Abbott’s third-generation MitraClip transcatheter heart valve repair device.
Alder hires Juno exec as CEO, Allergan brings in Abbott vet after investors demand change, and ResTORbio poaches Novartis researcher as clinical VP.